Teva Pharmaceutical Industries Limited (TEVA) : Analyst Rating Update

Teva Pharmaceutical Industries Limited (TEVA) : The consensus on Teva Pharmaceutical Industries Limited (TEVA) based on 19 analyst recommendation on the company stock is 1.5, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 13 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Teva Pharmaceutical Industries Limited (TEVA) : The highest level Teva Pharmaceutical Industries Limited (TEVA) is projected to reach is $100 for the short term and the lowest estimate is at $58. The consolidated price target from 18 rating analysts who initiate coverage on the stock is $74.3 and the possibility the share price can swing is $9.29.

Teva Pharmaceutical Industries Limited (NYSE:TEVA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $49.60 and $49.26 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $50.49. The buying momentum continued till the end and the stock did not give up its gains. It closed at $50.31, notching a gain of 0.68% for the day. The total traded volume was 4,724,267 . The stock had closed at $49.97 on the previous day.

Also, Credit Suisse initiates coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA). Credit Suisse has a Neutral rating on the shares. As per the latest report, the brokerage house announces the price target to $60 per share. The rating by the firm was issued on May 4, 2016. The company shares have dropped -17.68% from its 1 Year high price. On Jul 28, 2015, the shares registered one year high at $72.31 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $51.89 and the 200 Day Moving Average price is recorded at $56.40.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.